Cenobamate

ATC N03AX25 · 6 markets · 46 records

Cenobamate 6 markets · 46 records Forms

GB 12 records · 6 strengths

12.5 mgtabletOntozry 12.5mg/25mg tablets treatment initiation pack+1Ontozry 50mg tablets also in CA·ES·US
200 mgtabletOntozry 50mg tablets also in CA·ES·US
150 mgtabletOntozry 50mg tablets also in CA·ES·US
100 mgtabletOntozry 50mg tablets also in CA·ES·US
50 mgtabletOntozry 50mg tablets also in CA·ES·US
25 mgtabletOntozry 50mg tablets also in CA·US

CA 11 records · 6 strengths

12.5 mgtabletXcopri also in GB·ES·US
200 mgtabletXcopri also in GB·ES·US
150 mgtabletXcopri also in GB·ES·US
100 mgtabletXcopri also in GB·ES·US
50 mgtabletXcopri also in GB·ES·US
25 mgtabletXcopri also in GB·US

HK 9 records · 1 strengths

Records without a stated strength · 1 Xcopri、XCOPRI TABLETS 100MG AND 150MG (250MG DAILY DOSE MAINTENANCE PACK)、XCOPRI TABLETS 12.5MG AND 25MG (TITRATION PACK)

ES 7 records · 5 strengths

12.5 mgtabletONTOZRY ONTOZRY also in GB·CA·US
200 mgtabletOntozry 50mg tablets also in GB·CA·US
150 mgtabletOntozry 50mg tablets also in GB·CA·US
100 mgtabletOntozry 50mg tablets also in GB·CA·US
50 mgtabletOntozry 50mg tablets also in GB·CA·US

US 6 records · 6 strengths

12.5 mgtabletXcopri also in GB·CA·ES
200 mgtabletXcopri also in GB·CA·ES
150 mgtabletXcopri also in GB·CA·ES
100 mgtabletXcopri also in GB·CA·ES
50 mgtabletXcopri also in GB·CA·ES
25 mgtabletXcopri also in GB·CA

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 Ontozry 50mg tablets

Side-by-side table

Strength / form / release	US	GB	CA	ES	HK	EU
12.5 mg tablet	Xcopri	Ontozry 12.5mg/25mg tablets treatment initiation pack Ontozry 50mg tablets	Xcopri	ONTOZRY ONTOZRY	not recorded	not recorded
200 mg tablet	Xcopri	Ontozry 50mg tablets	Xcopri	Ontozry 50mg tablets	not recorded	not recorded
150 mg tablet	Xcopri	Ontozry 50mg tablets	Xcopri	Ontozry 50mg tablets	not recorded	not recorded
100 mg tablet	Xcopri	Ontozry 50mg tablets	Xcopri	Ontozry 50mg tablets	not recorded	not recorded
50 mg tablet	Xcopri	Ontozry 50mg tablets	Xcopri	Ontozry 50mg tablets	not recorded	not recorded
25 mg tablet	Xcopri	Ontozry 50mg tablets	Xcopri	not recorded	not recorded	not recorded
not disclosed unknown	not recorded	not recorded	not recorded	not recorded	Xcopri XCOPRI TABLETS 100MG AND 150MG (250MG DAILY DOSE MAINTENANCE PACK) XCOPRI TABLETS 12.5MG AND 25MG (TITRATION PACK)	Ontozry 50mg tablets

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

1 more strength/form rows are recorded only in HK · EU and are not shown in this table. Hay 1 filas de concentración/forma registradas solo en HK · EU que no se muestran en esta tabla. 另有 1 个规格/剂型仅在 HK · EU 有记录（未在本表显示）。另有 1 個規格/劑型僅在 HK · EU 有記錄（未在本表顯示）。

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.